Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EKTAY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EKTAY and 80,000+ other tickers.
See exactly how EKTAY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EKTAY and 80,000+ other tickers.
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management…
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
Elekta AB (publ) (EKTAY) Q4 2026 Earnings Call Transcript
Elekta AB (publ) is rated Buy with a 56 SEK ($6 ADR) price target, reflecting a 15% annualized return potential at 15x P/E. EKTAY's historical premium is no longer justified due to persistent earnings misses, slow growth, and margin challenges, but current valuation now offers upside. Recent improvements include a 300 bps EBIT margin rise, 4.3% yield with a 79% payout ratio, and positive book-to-bill and cash flow trends.
Elekta AB (publ) (EKTAY) Q3 2026 Earnings Call Transcript
Anteris Technologies Global (NASDAQ: AVR - Get Free Report) and Elekta (OTCMKTS:EKTAY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Volatility and Risk Anteris Technologies Global has a